by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
Background Disease-modifying therapies (DMTs) for Alzheimer’s disease (AD) have early evidence of efficacy. Widespread delivery of DMTs will require major service reconfiguration. Treatment pathways will need to include triaging for eligibility, regular infusions and...
by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
Two publications in JNNP explore the potential utility of therapies with differing mechanisms of action for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Querol et al evaluate the neonatal Fc receptor blocker rozanolixizumab, while...
by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
Driving a motor vehicle is an important skill set. Its evaluation is relevant to patients who had a stroke. These patients struggle to get back to driving because of physical deficits, including challenges from neglect and apraxia and the risk of unexpected future...
by Clinical Neuropsychologist | Friday, August 16, 2024 | Neurology
One hundred and seventeen years after Alzheimer described the condition that bears his name, the first treatments have been identified which appear to modify its course.1 2 These treatments are monoclonal antibodies which clear one of the presumed pathogenic proteins...
by Clinical Neuropsychologist | Wednesday, July 31, 2024 | Neurology
Purpose of review Inherited peripheral neuropathies can be divided into those diseases in which peripheral neuropathy is the sole or main feature of the disease (Charcot-Marie-Tooth disease) and those in which peripheral neuropathy is just one feature of a more...
by Clinical Neuropsychologist | Thursday, July 25, 2024 | Neurology
Purpose of review Leprosy is still an important cause of neuropathy. Late diagnosis is associated with development of severe nerve impairment. Recent findings early diagnosis and early treatment is essential in order to avoid disability and disease transmission....
